Johns Hopkins University Researchers To Clinically Assess Rosetta Genomics’ MiRview(TM) Squamous Assay

Rosetta Genomics, Ltd. (NASDQ: ROSG), a leader in the development of microRNA-based diagnostic and therapeutic products, announced today the initiation of a clinical assessment study with the Johns Hopkins University School of Medicine. The study will compare Rosetta Genomics’ miRview(TM) squamous, which differentiates squamous from non squamous non small cell lung cancer, with available immunohistochemistry methods.

More: continued here

Filed under: Clinical Trials on October 3rd, 2008